- Adjusted diluted earnings per share (EPS) was $0.78, ahead of expectations, supported by strong top-line performance and cost management.
- Adjusted gross margin was approximately 76%, reflecting product mix and expected savings from manufacturing optimization programs.
- Adjusted operating expenses declined 8% operationally, with decreases in both selling, general and administrative (SG&A) and research and development (R&D) expenses.
- Pfizer reported second quarter 2025 revenues of $14.7 billion, a 10% operational increase driven by growth in both U.S. and international markets.
- Recently launched and acquired products generated $4.7 billion in revenue year-to-date, growing approximately 15% operationally versus last year.
- Reported diluted EPS was $0.51, benefiting from an efficient operating structure and favorable tax rate changes.
- The company returned $4.9 billion to shareholders via dividends in the first half of 2025 and invested $4.7 billion in internal R&D.
Related items and other data are not available for this feed item.
Dafinchi